Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study. D'Sa S, Vos JMI, Barcellini W, Wardecki M, et al. Blood 2024;143:713-720.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

D'Sa S, Vos JMI, Barcellini W, Wardecki M, et al. Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study. Blood 2024;143:713-720.
PMID: 38085846